MENTAX

This brand name is authorized in Israel, Japan, United States

Active ingredients

The drug MENTAX contains one active pharmaceutical ingredient (API):

1 Butenafine UNII R8XA2029ZI - BUTENAFINE HYDROCHLORIDE

Butenafine is a benzylamine derivative with a mode of action similar to that of the allylamine class of antifungal drugs. Butenafine HCl is hypothesized to act by inhibiting the epoxidation of squalene, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. It is indicated for the topical treatment of the dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare). Read about Butenafine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MENTAX Cream	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D01AE23	Butenafine	D Dermatologicals → D01 Antifungals for dermatological use → D01A Antifungals for topical use → D01AE Other antifungals for topical use
Discover more medicines within D01AE23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4281
Country: JP	医薬品医療機器総合機構	Identifier(s): 2659708N1082, 2659708Q1062, 2659708R1076
Country: US	FDA, National Drug Code	Identifier(s): 0378-6151